Twice Daily Titration Study of Bifeprunox in Subjects With Schizophrenia

Solvay Pharmaceuticals

Overview

This study is to assess the safety and tolerability of a five-day titration schedule (using twice daily dosing for the first three days) to achieve the highest proposed dose of 40 mg daily. The study duration is two months.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

DOUBLE

Conditions

Schizophrenia Schizoaffective Disorder

Interventions

BifeprunoxDRUG

Eligibility

Sex: ALLMin age: 18 YearsMax age: 55 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Subjects who have current diagnosis of Schizophrenia or Schizoaffective disorder * Body weight of 100-250 lbs * Male or females * 18-55 years of age Exclusion Criteria: * Subjects who are acutely psychotic * Subjects with current Axis I primary psychiatric diagnosis other than schizophrenia, at significant risk of suicide

Locations (1)

Site 1

National City, California, United States

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.